First in Human Study of YB1-X7 Injection

NCT06889675 | Not Yet Recruiting

• 1 other identifier: ZXK24-D1-P001
• Study Type: interventional
• Target: 36
• Locations: 0 countries
• Sites: N/A

Brief Summary

This clinical trial is an open-label, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetic, and preliminary efficacy of YB1-X7 injection in subjects with advanced solid tumors. YB1-X7 injection is an attenuated Salmonella-based tumor therapy. It selectively accumulates in hypoxic tumor regions while being rapidly cleared from normal organs. After proliferating in the tumor microenvironment, YB1-X7 invades tumor cells and releases its therapeutic payload, leading to tumor cell death and tumor regression. Conditions：To treat subjects with advanced and/or metastatic solid tumors who do not to respond to conventional standard treatment or who lack effective standard treatment.

Conditions

Advanced Solid Tumors

Outcome Measures

Primary Outcomes (3)

• Incidence of dose limiting toxicity (DLTs)

  DLT is defined as any toxic reaction associated with the study drug occurring within 28 days after the first administration, graded refer to the NCI Common Terminology Criteria for Adverse Events (CTCAE v5.0).

  Up to 28 days post first dose.

• Adverse events (AEs)

  An AE is any untoward medical occurrence in a patient or clinical investigation patient, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.

  From receiving study drug and throughout the study, until 28 days after the last dosing

• Serious adverse events(SAEs)

  A serious adverse event (SAE) refers to any medical event that results in: * Death * Life-threatening conditions ③ Permanent or severe disability or loss of function ④ Hospitalization or prolonged hospitalization ⑤ Congenital abnormalities or birth defects Other important medical events, which may not immediately threaten life, death, or require hospitalization, but still necessitate medical interventions to prevent one of the above outcomes, are also considered serious. Examples include: * Urgent treatments in an emergency room * Allergic bronchospasm (even if not requiring hospitalization) ③ Severe cachexia or seizures ④ Drug dependence or addiction Death due to drug-related adverse events (e.g., ventricular fibrillation) is classified as an SAE. However, if the death is due to the progression of the underlying disease (e.g., cancer) and the adverse event was mild (e.g., a rash or abdominal pain), it is not considered an SAE.

  From receiving study drug and throughout the study, until 28 days after the last dosing.

Secondary Outcomes (11)

• YB1-X7 level in blood for PK analysis

  Before the first administration up to 28 days after the last dosing.

• Immunogenicity (anti-drug antibodies)

  Before the first administration up to 28 days after the last dosing.

• YB1-X7 level in blood for bacterial shedding.

  Before the first administration up to 28 days after the last dosing.

• YB1-X7 shedding level analysis in urine, saliva, faeces using qPCR

  Before the first administration up to 28 days after the last dosing.

• Cytokines

  Before the first administration up to 28 days after the last dosing.

Study Arms (2)

YB1-X7 Injection Intratumoral Injection

EXPERIMENTAL

YB1-X7 injection will be injected into the target lesion intratumorally. Three cohorts (low, medium, and high) will be assigned. The standard 3+3 dose-escalation design will be applied to explore dose limiting toxicity in 3 sequential cohorts with 3- 6 patients.

Drug: YB1-X7 Injection (IT)

YB1-X7 Injection Intravenous Infusion

EXPERIMENTAL

YB1-X7 injection will be administered as an IV infusion through a dedicated line catheter over 2 hours.Three cohorts (low, medium, and high) will be assigned. The standard 3+3 dose-escalation design will be applied to explore dose limiting toxicity in 3 sequential cohorts with 3- 6 patients.

Drug: YB1-X7 Injection (IV)

Interventions

YB1-X7 Injection (IT) DRUG

Intratumoral injection

Also known as: YB1-X7

YB1-X7 Injection Intratumoral Injection

YB1-X7 Injection (IV) DRUG

Intravenous infusion

Also known as: YB1-X7

YB1-X7 Injection Intravenous Infusion

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years, no gender limitatlon
• Subjects with advanced or metastatic solid tumors confirmed by pathological histology.
• Subjects with advanced malignant solid tumors for whom standard treatment has failed or no other effective standard treatment available.
• At least one measurable solid tumor by RECIST 1.1.
• Subjects assigned to intratumoral injection must have at least one tumor that is suitable for biopsy or intratumoral injection.
• Life expectancy must be at least 3 months.
• Eastern Cooperative Oncology Group (ECOG) performance status score 0-1.
• Male and female subjects of childbearing potential should take effective contraceptive measures.
• ① Fertile women and men must agree to use acceptable contraceptive methods from the start of informed consent until at least 6 months after the last administration.
• Laboratory blood test results during the screen period:
• (1)No blood cell growth factors received within 14 days prior to testing.
• ① Absolute neutrophil count (ANC)≥1.5×109/L.
• ② Platelets≥90×109/L. Hemoglobin ≥90 g/L (blood transfusion is allowed to correct). (2) Serum albumin \>30 g/L, total bilirubin \<1.5×ULN, ALT and AST \<2.5×ULN; for subjects with liver metastasis, ALT and AST \<5×ULN; creatinine clearance ≥50 mL/min (Cockcroft-Gault formula) or Cr \<1.5×ULN; (3) Prothrombin time (PT) and activated partial thromboplastin time (aPTT) \<1.5×ULN.
• \. Subjects understand the study and willing to sign the informed consent form.

You may not qualify if:

• Pregnant or breastfeeding women. Subjects known to have a history of abuse of psychiatric drugs, alcoholism, or drug use.
• Subjects who have previously undergone oncolytic bacteria treatment. 4.Subjects planning to surgery, radiation therapy, or other local treatments for target lesions during the study.
• Subjects known to be allergic to the study drug or any of its excipients. 6.Subjects allergic or intolerant to antibiotics sensitive to Salmonella, such as amikacin cefpirome, ciprofloxacin,cefotaxime,meropenem.
• Subjects currently using antibiotics. 8.Subjects who have not recovered fom adverse reactions of prior treatments (treatment-related toxicity grade≤2, except for hair loss, pigmentation, and other tolerable events determined by the investigator).
• Subjects with active auto-immune diseases or prior diseases with recurrence potential (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), except for clinically stable autoimmune thyroiditis.
• Subjects with active or uncontrolled infections or unexplained fever≥38.5℃, including but not limited to bacterial infections, tuberculosis, herpes virus infections syphilis infections.
• Subjects who underwent major surgery within 3 months prior to the first dose of the study drug (except for biopsies for diagnostic purposes).
• Subjects who have received any anti-tumor treatment within 28 days or 5 half-lives prior to the first dose of the study drug, including chemotherapy, cell therapy, gene therapy, immunotherapy,biological agents, hormone therapy, targeted therapy, tumor drug embolization therapy.
• Subjects who received radiation therapy within 28 days prior to the first dose of the study drug (except for local radiation therapy for pain relief).
• Subjects who receive (live attenuated) virus vaccines: within 28 days prior to the first dose of the study drug, or during the study period or within 60 days after the last dose of the study drug.
• Subjects who have used immunosuppressive drugs within 14 days prior to the first dose of the study drug (i.e., prednisone≥10 mg/day, dexamethasone≥1.5 mg/day), except for corticosteroid nasal sprays and inhaled corticosteroids or physiological doses of systemic corticosteroids (i.e., prednisone not exceeding 10 mg/day)or equivalent physiologica doses of other corticosteroids.
• \. Subjects with known, uncontrolled, or symptomatic active central nervous system conditions.
• \. Subjects with existing clinical symptoms or pooely controlled heart disease:
• New York Heart Association (NYHA) class ≥II;
• Unstable angina;

Sponsors & Collaborators

• Shanghai Salvectors Biotechnology LTD.: lead

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Both administration routes will have three dose cohorts (low, medium, and high dose) , each cohort will have 3-6 subjects, following the standard 3+3 dose-escalation design, with single-dose multiple administrations in an escalating dose scheme. 1. If no toxicities (DLTs ) in a dose cohort, the dose escalation study for the next dose cohort may proceed. 2. If 1 of 3 subjects experience DLTs in the same dose cohort during the DLT observation period, 3 additional subjects will be enrolled in that dose cohort. If 0 of 3 newly enrolled msubjects experience DLTs, dose escalation may continue to the next cohort, if one or more DLTs occur among the newly enrolled three subjects, dose escalation will be stopped. 3. If 2 of 3 or more subjects experience DLT, or 2 of 6 or more subjects experience DLT dose escalation will be stopped.

Study Record Dates

• First Submitted: March 10, 2025
• First Posted: March 21, 2025
• Study Start: March 15, 2025
• Primary Completion (Estimated): January 31, 2027
• Study Completion (Estimated): March 31, 2027
• Last Updated: March 21, 2025

Record last verified: 2025-03

Data Sharing

• IPD Sharing: Will not share